G
Giuseppe Derosa
Researcher at University of Pavia
Publications - 374
Citations - 11198
Giuseppe Derosa is an academic researcher from University of Pavia. The author has contributed to research in topics: Diabetes mellitus & Insulin resistance. The author has an hindex of 52, co-authored 361 publications receiving 9654 citations. Previous affiliations of Giuseppe Derosa include University of Bologna & Università telematica San Raffaele.
Papers
More filters
Journal ArticleDOI
Sulfonylureas and their use in clinical practice
Daniele Sola,Luca Rossi,Gian Piero Carnevale Schianca,Pamela Maffioli,Marcello Bigliocca,Roberto Mella,Francesca Corlianò,Gian Paolo Fra,Ettore Bartoli,Giuseppe Derosa +9 more
TL;DR: It is concluded that sulfonylureas are still the most used anti-diabetic agents: maybe this is due to their lower cost, to the possibility of mono-dosing and to the presence of an association with metformin in the same tablet.
Journal ArticleDOI
α-Glucosidase inhibitors and their use in clinical practice
Giuseppe Derosa,Pamela Maffioli +1 more
TL;DR: Compared to miglitol and voglibose, acarbose seems to have some additive effects such as stabling carotid plaques, and reducing inflammation, while α-glucosidase inhibitors also proved to reverse impaired glucose tolerance to normal glucose tolerance.
Journal ArticleDOI
Effects of a Restricted Sleep Regimen on Ambulatory Blood Pressure Monitoring in Normotensive Subjects
TL;DR: The influence of sleep deprivation during the first part of the night on 24-h ambulatory blood pressure monitoring (ABPM) was studied in 18 normotensive subjects, with main differences observed at dawn, before awakening, and during the morning after the recovery sleep, when SBP and HR significantly increased.
Journal ArticleDOI
A role for quercetin in coronavirus disease 2019 (COVID-19).
TL;DR: Quercetin has a theoretical, but significant, capability to interfere with SARS‐CoV‐2 replication, with the results showing this to be the fifth best compound out of 18 candidates.
Journal ArticleDOI
Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study.
TL;DR: 12-month telmisartan treatment produced a significantly greater reduction in DBP than eprosartan and significantly improved plasma lipids, even if it is not clear about the relationship between angiotensin-II receptor blockade and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibition.